Medical Device Growth In Emerging Markets: Lessons From Other Industries

Many other industries underwent a similar globalization process a decade ago and essentially reinvented their approaches for the mid-tier of fast growing economies. We believe medical device MNCs can leverage many components of these strategies. Although each industry has unique dynamics and none are perfect parallels, we have focused on the similarities where we believe significant lessons can be learned.

Emerging markets are widely recognized as one of the most important growth frontiers for medical devices. However, multinational players are still trying to unravel the nature of each market and the exact winning formula for success. To date, most multinational companies (MNCs) have focused on the premium customer segment with pre-existing products and commercial models, but we believe the next wave of growth will be in the largely untapped mid-tier of these markets. Emerging markets are experiencing a rise of their middle class, increased access to care and new feature versus price trade-offs that will require rethinking existing strategies and business models.

Many other industries underwent a similar globalization process a decade ago and essentially reinvented their approaches for the mid-tier of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By 

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy